Skip to main content

CD30 Bispecific Antibody-Armed T Cells

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

  • RegistryNCT05544968
  • PhasePhase 1
  • StatusRecruiting
  • ConditionRelapsed or Refractory Hodgkin Lymphoma and CD30+ Lymphomas
  • SponsorMedical College of Wisconsin
How CD30-Armed T Cells worksNCT055449681 min

What the film says

Read the transcript

This trial is for adults with Hodgkin lymphoma or other CD30 positive blood cancers that have come back or not responded to treatment.

The idea: collect the patient's own T cells, activate them, and coat them with a bispecific antibody that grabs CD30 on cancer cells and CD3 on the T cell. The armed T cells are then given back. This is the first time this treatment is tested in people.

The study looks at safety, feasibility, and how well it works.

This phase 1 study plans 42 patients. At the Medical College of Wisconsin in Milwaukee, Guru Subramanian Guru Murthy leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT05544968

    Adults; relapsed/refractory CD30+ cancers incl. Hodgkin; Own T cells activated, armed with CD30xCD3 bispecific; First-in-human; Safety, feasibility, efficacy (+1 more lines)

The drug

What is being tested.

anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells

Hematopoietic agent that helps form white blood cells.

Non-randomized, single arm, dose escalating, Phase I study evaluating the feasibility and safety of a novel anti-CD30 biAb-AATC product for adult patients with relapsed/refractory CD30+ cancer. Following T-cell collection patients are recommended to receive a bridging chemotherapy for 21 days while product is being generated and quality control assessed.

The study

How the trial runs.

This first-in-human trial will assess the safety, feasibility, and efficacy of an immunotherapy with a novel CD30 antibody conjugated to a CD3 antibody that is preloaded onto a patient's own T-cells, generating a CD30 bispecific antibody-armed, anti-CD3-activated, autologous T-cells (CD30 biAb-AATC).

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Diagnosis: Patients must have had histologic or cytologic verification of the below qualified malignancy. The pathology report for the diagnosis under which the patient is being enrolled and associated molecular diagnostic reports must be submitted.
  • i. Second or greater recurrence or refractory to at least 2 prior therapeutic regimens.
  • ii. Any relapse after HSCT.
  • ii. Any relapse after HSCT or CAR T cell therapy.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.